Fiscal 2023 revenue increased 11% year-over-year to $59.6 million
Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68
Simulations Plus to host its Investor Day on November 14, 2023

Fiscal 2023 revenue increased 11% year-over-year to $59.6 million
Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68
Simulations Plus to host its Investor Day on November 14, 2023
In the realm of pharmaceutical R&D, the quest for enhanced predictive accuracy and efficiency for Fed State PBPK models has never been more pressing.
In this study, we use machine learning algorithms with QM-derived COSMO-RS descriptors, along with Morgan fingerprints, to predict the absolute solubility of drug-like compounds.
A TIM-1 model is an in vitro gastrointestinal (GI) simulator considering crucial physiological parameters that will affect the in vivo drug release process.
In the Ionization Prediction Summit webinar series, leading industry experts will explain ionization, how ionization modeling works, how ionization models are influenced by the large amounts of industrial data...
Antipsychotic drugs formulated as long-acting injectables (LAIs) significantly improve patient compliance compared to regimens that require daily oral administration.
Fexofenadine (FEX), a H1-receptor antagonist used in the treatment of allergic rhinitis and chronic idiopathic urticaria, undergoes minimal metabolism and transporters play a major role in its absorption and disposition.
Buccal delivery allows bypassing first-pass metabolism
Unleash the Power of AI for Early Drug Discovery
Accurate and actionable ADMET predictions rely on premium data and proven algorithms.
Use CDIAM and the AIDD platform in ADMET Predictor to take your program from target indication to optimized lead candidate
Metformin is among the most prescribed medications worldwide and the first-line therapy for type 2 diabetes.
Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug...
Using ionization modeling to inform drug discovery and decision-making
Your model is only as good as your data!
GastroPlus® Newsletter October 2023
Predict and prevent metabolic dysfunction-associated fatty liver disease and MASH.
Trofinetide, a synthetic analog of glycine-proline-glutamate, was approved by the US Food and Drug Administration in March 2023 for the treatment of...
M8891 is a selective and reversible inhibitor of methionine aminopeptidase 2 (MetAP2).